Overview
Chelation therapy products are available via prescription. Prescription products are approved for conditions such as heavy metal toxicity and very high calcium levels. Some companies also sell chelation therapy products as supplements. DMSA (2,3-Dimercaptosuccinic Acid), DMPS (2,3-Dimercaptopropane-1-Sulfonate), and EDTA (ethylenediamene tetraacetic acid) are the chemicals most often sold this way.
People use non-prescription chelation therapy products for Alzheimer disease, arsenic poisoning, autism, ADHD, Parkinson disease, and many other conditions, but there is no good scientific evidence to support these uses. Non-prescription chelation therapy products might also be unsafe.
The FDA warns consumers to be wary of non-prescription chelation therapy products marketed for the treatment or prevention of any disease. These products have not been approved or reviewed by the FDA and can cause serious adverse effects. Discuss the use of prescription chelation therapy products with a healthcare provider.
Uses & Effectiveness ?
We currently have no information for CHELATION THERAPY PRODUCTS overview.
Side Effects
Special Precautions and Warnings
Pregnancy and breast-feeding: Unapproved, non-prescription chelation therapy products are possibly unsafe when used during pregnancy or while breast-feeding. Using prescription chelation therapy products for unapproved uses is also possibly unsafe. These products can cause severe side effects, including dehydration, kidney failure, and death. Avoid use.
Children: Unapproved, non-prescription chelation therapy products are possibly unsafe for use in children. Using prescription chelation therapy products for unapproved uses is also possibly unsafe. These products can cause severe side effects, including dehydration, kidney failure, and death. Avoid use.
Diabetes: Chelation therapy products might make blood sugar control worse in people with diabetes.
Low calcium levels: Chelation therapy products might reduce calcium levels, making calcium levels even lower in people who already have low calcium.
Low potassium levels: Chelation therapy products might reduce potassium levels, making potassium levels even lower in people who already have low potassium.
Low magnesium levels: Chelation therapy products might reduce magnesium levels, making magnesium levels even lower in people who already have low magnesium.
Kidney disease: Chelation therapy products might make existing kidney disease worse.
Liver disease: Chelation therapy products might make existing liver disease worse.
Seizure disorders: TChelation therapy products might increase the risk for seizures in people with epilepsy or other seizure disorders.
Interactions ?
Insulin interacts with CHELATION THERAPY PRODUCTS
Chelation therapy products such as EDTA can decrease blood sugar. Insulin is also used to decrease blood sugar. Taking chelation therapy products along with insulin can cause serious decreases in blood sugar. Monitor your blood sugar closely. The dose of your insulin might need to be changed.
Major Interaction
Do not take this combination
Warfarin (Coumadin) interacts with CHELATION THERAPY PRODUCTS
Warfarin is used to slow blood clotting. Chelation therapy products such as EDTA might decrease the effects of warfarin. This might increase the risk of clotting. Be sure to have your blood checked regularly. The dose of your warfarin might need to be changed.
Water pills (Diuretic drugs) interacts with CHELATION THERAPY PRODUCTS
Chelation therapy products such as EDTA might reduce potassium levels. "Water pills" can also decrease potassium levels. Taking chelation therapy products along with "water pills" might make potassium levels drop too low.
Moderate Interaction
Be cautious with this combination
Dosing
Some chelation therapy products are available via prescription. Discuss the use of these products with a healthcare provider.
Adams JB, Baral M, Geis E,. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol. 2009;9:17. View abstract.
Adams, J. B., Baral, M., Geis, E., Mitchell, J., Ingram, J., Hensley, A., Zappia, I., Newmark, S., Gehn, E., Rubin, R. A., Mitchell, K., Bradstreet, J., and El-Dahr, J. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results. BMC.Clin.Pharmacol. 2009;9:16. View abstract.
Akbayram S, Dogan M, Akgun C, et al. EDTA-dependent pseudothrombocytopenia in a child. Clin Appl Thromb Hemost 2011;17:494-6. View abstract.
American College of Medical Toxicology and The American Academy of Clinical Toxicology. https://www.choosingwisely.org/clinician-lists/american-college-academy-medical-toxicology-chelation/. Accessed May 18, 2022.
Anon. Questions and Answers about chelation therapy. American Heart Association 2000. Available at: www.americanheart.org. (Accessed 17 November 2000).
Atwood KC, Woeckner E. In pediatric fatality, edetate disodium was no accident. Clin Toxicol (Phila) 2009;47(3):256. View abstract.
Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 2008;46(10):1083-4. View abstract.
Beasley R, Fishwick D, Miles JF, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998;18:130-9. View abstract.
Blaucok-Busch E, Amin OR, Dessoki HH, Rabah T. Efficacy of DMSA therapy in a sample of Arab children with autistic spectrum disorder. Maedica (Bucur). 2012;7(3):214-21. View abstract.
Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics 2006;118(2):e534-6. View abstract.
Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep 2006;55(8):204-7. View abstract.
Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs 1996;10:78-86. View abstract.
Chappell LT, Wilson J, Ernst E. Chelation therapy for vascular disease. Circulation 1999;99:164-5.
Chappell LT. EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Altern Ther Health Med 1995;1:53-7. View abstract.
Chisolm JJ Jr. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. J Toxicol Clin Toxicol 1992;30:493-504.
Christensen K, Theilade D. Edta chelation therapy: an ethical problem. Med Hypotheses 1999;53:69-70. View abstract.
Cohen JP, Ruha AM, Curry SC, et al. Plasma and urine dimercaptopropanesulfonate concentrations after dermal application of transdermal DMPS (TD-DMPS). J Med Toxicol 2013;9(1):9-15. View abstract.
Elihu N, Anandasbapathy S, Frishman WH. Chealtion therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol 1998;38:101-5. View abstract.
Ellsworth AJ, Witt DM, Dugdale DC, et al. Medical Drug Reference. Saint Louis, MO: Mosby-Year Book Inc 1998:302-3.
Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. Am Heart J 2000;140:139-41. View abstract.
Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation 1997;96:1031-3. View abstract.
Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes 2014;7:15-24. View abstract.
Food and Drug Administration. Questions and answers on unapproved chelation products. https://www.fda.gov/drugs/medication-health-fraud/questions-and-answers-unapproved-chelation-products. Accessed May 18, 2022.
Fountain JS, Reith DM. Dangers of "EDTA". N Z Med J 2014;127:126-7. View abstract.
Golan A, Savir H, Bar-Meir S, et al. Band keratopathy due to hyperparathyroidism. Ophthalmologica 1975;171:119-22. View abstract.
Gordon RA, Roberts G, Amin Z, et al. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Arch Pediatr Adolesc Med 1998;152:1100-4. View abstract.
Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy 2002;22:1067-9.. View abstract.
Green S. Chelation therapy: unproven claims and unsound theories. Quackwatch 2000. Available at: https://www.quackwatch.org (Accessed 17 November 2000).
Grier MT, Meyers DG. So much writing, so little science: a review of 37 years literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504-9. View abstract.
Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. J Intern Med 1992;231:261-7. View abstract.
Gundling K, Ernst E. Complementary and alternative medicine in cardiovascular disease: what is the evidence it works? WJM 1999;171:191-4.
Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
Heimbach J, Rieth S, Mohamedshah F, et al. Safety assessment of iron EDTA [sodium iron (Fe(3+) ethylenediaminetetraacetic acid]: summary of toxological fortification and exposure data. Food Chem Toxicol 2000;38:99-111. View abstract.
James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). Cochrane Database Syst Rev 2015;5(5):CD010766. View abstract.
Kidd PM. Integrative cardiac revitalization: bypass surgery, angioplasty, and chelation. Benefits, risks, and limitations. Altern Med Rev 1998;3:4-17. View abstract.
Kitchell JR, Palmon F, Aytan N, Meltzer LE. The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiology 1963;11:501-6.
Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA. 2002;287(4):481-6. View abstract.
Lacy CF, Armstrong LL, Ingrim NB, et al. Drug Information Handbook. 6th ed. Hudson, OH:Lexi-Comp Inc 1998:439-41.
Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J 2000;140:4-5.
Lamas GA, Boineau R, Goertz C, et a. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J 2014;168:37-44.e5. View abstract.
Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 2013;309:1241-50. View abstract.
Lamas GA, Hussein SJ. EDTA chelation therapy meets evidence-based medicine. Complement Ther Clin Pract 2006;12(3):213-5. View abstract.
Lee CE. Federal regulation of unapproved chelation products. J Med Toxicol 2013;9(4):313-7. View abstract.
Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med 1999;130:7-13. View abstract.
Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23(4):303-8. View abstract.
Lyon AF, DeGraff AC. Reappraisal of digitalis. X. Treatment of digitalis toxicity. Am Heart J 1967;73:835-7.
Mehbod H. Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA 1967;201:972-4.
Mortensen ME, Walson PD. Chelation therapy for childhood lead poisoning. The changing scene in the 1990s. Clin Pediatr (Phila) 1993;32:284-91.
Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA. 2013 Mar 27;309(12):1293-4. View abstract.
Ohashi N, Nakamura K, Inokuchi R, et al. EDTA-dependent pseudothrombocytopenia complicated by eosinophilic pneumonia. Am J Emerg Med 2013;31:1157.e5-7. View abstract.
Ohno N, Kobayashi M, Hayakawa S, et al. Transient pseudothrombocytopenia in a neonate: transmission of a maternal EDTA-dependent anticoagulant. Platelets 2012;23:399-400. View abstract.
Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1998;27:41-9. View abstract.
Popovici A, Geschickter CF, Reinovsky A, Rubin M. Experimental control of serum calcium levels in vivo. Proc Soc Exp Biol Med 1950;74:415-7.
Russo PA, Banovic T, Wiese MD, et al. Systemic allergy to EDTA in local anesthetic and radiocontrast media. J Allergy Clin Immunol Pract 2014;2:225-9. View abstract.
Sahin C, Kirli I, Sozen H, Canbek TD. EDTA-induced pseudothrombocytopenia in association with bladder cancer. BMJ Case Rep 2014;2014. pii: bcr2014205130.View abstract.
Schubert J. Chelation in medicine. Sci Am 1966;214:40-50.
Sen BH, Akdeniz BG, Denizci AA. The effect of ethylenediamine-tetraacetic acid on Candida albicans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:651-5.. View abstract.
Shi X, Lin Z, He L, et al. Transient appearance of EDTA-dependent pseudothrombocytopenia in a postoperative patient with sepsis: A case report. Medicine (Baltimore) 2017;96:e6330 View abstract.
Shrand H. Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1961;1:310-2.
Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991;162:122-5. View abstract.
Soffer A. Chelation therapy for arteriosclerosis. JAMA 1975;233:1206-7. View abstract.
Stangle DE, Smith DR, Beaudin SA, Strawderman MS, Levitsky DA, Strupp BJ. Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect 2007;115(2):201-9. View abstract.
Surawica B. Use of the chelating agent, EDTA, in digitalis intoxication and cardiac arrhthymias. Prog Cardiovasc Dis 1960;2:432-43.
Taweechaisupapong S, Doyle RJ. Sensitivity of bacterial coaggregation to chelating agents. FEMS Immunol Med Microbiol 2000;28:343-6. View abstract.
Van der Linde AAA, Pillen S, Gerrits GPJM, Bouwes Bavinck JN. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. Clin Toxicol (Phila). 2008;46(5):479-81. View abstract.
van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994;90:1194-9. View abstract.
Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev 2002;(4):CD002785. View abstract.
Wax PM. Current use of chelation in American health care. J Med Toxicol 2013;9(4):303-7. View abstract.
Wenzel F, Lasshofer R, Rox J, et al. Transient appearance of postoperative EDTA-dependent pseudothrombocytopenia in a patient after gastrectomy. Platelets 2011;22:74-6. View abstract.
Yanoff M, Duker JS. Ophthalmology. Saint Louis, MO: Mosby-Year Book Inc., 1999.
Zatlin GS, Senaldi EM, Bruckheim AH. Adult lead poisoning. Am Fam Physician 1985;32:137-43. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.